NCT02759601 - Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Tefinostat

Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage

Trial Locations (4)

Barts Health NHS Trust, London

Beatson Cancer Centre, Glasgow

Clatterbridge Cancer Centre, Liverpool

University College London Hospital, London